Mervin Smith - IRhythm Technologies Executive Operations
| IRTC Stock | USD 82.32 8.33 11.26% |
Executive
Mervin Smith is Executive Operations of iRhythm Technologies
| Age | 49 |
| Address | 699 8th Street, San Francisco, CA, United States, 94103 |
| Phone | 415 632 5700 |
| Web | https://www.irhythmtech.com |
Latest Insider Transactions
IRhythm Technologies Management Efficiency
The company has return on total asset (ROA) of (0.0893) % which means that it has lost $0.0893 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0334) %, meaning that it created substantial loss on money invested by shareholders. IRhythm Technologies' management efficiency ratios could be used to measure how well IRhythm Technologies manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.3. In addition to that, Return On Capital Employed is expected to decline to -0.4. At present, IRhythm Technologies' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 47.3 M, whereas Total Assets are forecasted to decline to about 287.1 M.Similar Executives
| Found 13 records | EXECUTIVE Age | ||
| Michael MD | Nutex Health | 53 | |
| Yew CPA | EUDA Health Holdings | 56 | |
| Richa Gujarati | Heartbeam | N/A | |
| Amanda Hammer | Mangoceuticals, Common Stock | 38 | |
| Kenneth Persen | Heartbeam | N/A | |
| Michael Campana | Healthcare Triangle | N/A | |
| Esq JD | Nutex Health | 60 | |
| Damian David | Healthcare Triangle | N/A | |
| MBA FACHE | Nutex Health | N/A | |
| Timothy Cruickshank | Heartbeam | 43 | |
| Eugene Johnston | Mangoceuticals, Common Stock | 60 | |
| Anand Kumar | Healthcare Triangle | 50 | |
| Abhay Borwankar | Healthcare Triangle | N/A | |
Management Performance
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.0893 |
iRhythm Technologies Leadership Team
Elected by the shareholders, the IRhythm Technologies' board of directors comprises two types of representatives: IRhythm Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IRhythm. The board's role is to monitor IRhythm Technologies' management team and ensure that shareholders' interests are well served. IRhythm Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IRhythm Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Chad Patterson, Chief Officer | ||
| Brice CPA, Chief Officer | ||
| Mazi Kiani, VP Regulatory | ||
| Daniel Wilson, Executive Relations | ||
| Mintu MD, Chief Officer | ||
| MS MD, Chief Innovation | ||
| Mervin Smith, Executive Operations | ||
| Patrick JD, Chief Counsel | ||
| Mark Day, Executive Vice President of Research and Development | ||
| Stephanie Zhadkevich, Director Relations | ||
| Douglas Devine, Executive Advisor | ||
| Marc Rosenbaum, Senior Officer | ||
| David Vort, Executive Vice President of Sales | ||
| Reyna Fernandez, Ex Officer | ||
| Sumi Shrishrimal, Executive Officer | ||
| Quentin Blackford, CEO President |
IRhythm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IRhythm Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.0893 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 2.53 B | ||||
| Shares Outstanding | 31.3 M | ||||
| Shares Owned By Insiders | 0.78 % | ||||
| Shares Owned By Institutions | 99.22 % | ||||
| Number Of Shares Shorted | 2.74 M | ||||
| Price To Earning | (36.08) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iRhythm Technologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IRhythm Technologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Irhythm Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Irhythm Technologies Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iRhythm Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade IRhythm Stock refer to our How to Trade IRhythm Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IRhythm Technologies. If investors know IRhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IRhythm Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.85) | Revenue Per Share 18.045 | Quarterly Revenue Growth 0.184 | Return On Assets (0.09) | Return On Equity (1.03) |
The market value of iRhythm Technologies is measured differently than its book value, which is the value of IRhythm that is recorded on the company's balance sheet. Investors also form their own opinion of IRhythm Technologies' value that differs from its market value or its book value, called intrinsic value, which is IRhythm Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IRhythm Technologies' market value can be influenced by many factors that don't directly affect IRhythm Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IRhythm Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if IRhythm Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IRhythm Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.